How long does average survival extend during treatment with enzalutamide?

Enzalutamide (also known as enzalutamide) is an oral androgen receptor inhibitor, mainly used to treat patients with metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). It inhibits the growth and spread of prostate cancer cells by blocking the androgen signaling pathway. In recent years, a number of international large-scale clinical trials have confirmed the significant efficacy of enzalutamide in prolonging the survival of patients, making it one of the important drugs for the treatment of advanced prostate cancer.

In the field ofmCRPC, the efficacy of enzalutamide is particularly outstanding. According to the results of the PREVAIL study, for patients with metastatic castration-resistant prostate cancer who have not yet received chemotherapy, enzalutamide significantly prolonged overall survival (OS), with a median overall survival of 32.4 months, compared with the placebo group 30.2 months, which improved the survival time by more than 2 months. At the same time, the progression-free survival (PFS) improved even more significantly, reaching more than 20 months. If the patient has not received chemotherapy drugs such as docetaxel before, the survival benefit will be more significant.

In patients with non-metastatic castration-resistant prostate cancer (nmCRPC), the PROSPER study showed that enzalutamide can significantly prolong metastasis-free survival. (MFS), reaching 36.6 months, which was extended by nearly two years compared with 14.7 months in the placebo group. In addition, in terms of overall survival, later follow-up also confirmed that enzalutamide can help prolong overall survival time and delay the progression of the disease to the metastatic stage, significantly improving patients' quality of life and treatment confidence.

In summary, enzalutamide has shown good survival benefits in the treatment of prostate cancer patients at different stages. Although the specific extension time varies depending on the patient's individual condition, previous treatment experience, etc., overall, the median survival time can be extended by 2-4 years. For patients with advanced prostate cancer, enzalutamide not only provides longer survival time, but also provides more possibilities for improving quality of life and delaying chemotherapy. Patients should scientifically evaluate the indications and use this drug rationally under the guidance of a professional doctor.

Reference materials:https://www.drugs.com/